Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Ani Pharmaceuticals' Liabilities and Shareholders Equity rose 938.15% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 3228.65%. This contributed to the annual value of $1.3 billion for FY2024, which is 4193.56% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.4 billion, which was up 938.15% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q3 2025 and a low of $463.8 million during Q1 2021
  • Its 5-year average for Liabilities and Shareholders Equity is $897.4 million, with a median of $859.3 million in 2023.
  • The largest annual percentage gain for Ani Pharmaceuticals' Liabilities and Shareholders Equity in the last 5 years was 6730.59% (2021), contrasted with its biggest fall of 381.33% (2021).
  • Ani Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $771.6 million in 2021, then decreased by 1.49% to $760.1 million in 2022, then rose by 18.99% to $904.4 million in 2023, then surged by 41.94% to $1.3 billion in 2024, then increased by 9.7% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.